FDAsafety guidance66% confidence
FDA Accepts First In Silico Drug Development Tool Under ISTAND Program to Help Predict Drug-Induced Liver Injury
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for GSK; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Infectious Disease · Antifungal
- Sub-indication
- General
Related signal: FDA Accepts Supplement for Brexafemme (Ibrexafungerp) by GlaxoSmithKline